Evidence map›Paper›PMID 42847334›Full record

ReviewEuropean journal of immunology2026

CD39 on CD8

Manolo Sambucci, Daniela Fenoglio, Francesca Ferrera, Laura Camporesi, Andrea Lagazio, Giovanna Borsellino, Luca Battistini, Gilberto Filaci

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in European journal of immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Manolo SambucciDepartment of Internal Medicine and Medical Specialities (DIMI), University of Genova, Genoa, Italy.ORCID https://orcid.org/0000-0003-1124-7327
Daniela FenoglioDepartment of Internal Medicine and Medical Specialities (DIMI), University of Genova, Genoa, Italy.ORCID https://orcid.org/0000-0001-9532-6473
Francesca FerreraDepartment of Internal Medicine and Medical Specialities (DIMI), University of Genova, Genoa, Italy.
Laura CamporesiDepartment of Internal Medicine and Medical Specialities (DIMI), University of Genova, Genoa, Italy.
Andrea LagazioDepartment of Experimental Medicine (DIMES), University of Genoa, Genoa, Italy.ORCID https://orcid.org/0009-0007-4482-3614
Giovanna BorsellinoNeuroimmunology Unit, LIFE Institute for Research and Health Care - Santa Lucia IRCCS, Rome, Italy.ORCID https://orcid.org/0000-0002-4227-6481
Luca BattistiniNeuroimmunology Unit, LIFE Institute for Research and Health Care - Santa Lucia IRCCS, Rome, Italy.
Gilberto FilaciDepartment of Internal Medicine and Medical Specialities (DIMI), University of Genova, Genoa, Italy.ORCID https://orcid.org/0000-0001-6445-8414

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

CD39 (ENTPD1) occupies a paradoxical position in the immunology of solid tumours. On CD8

Indexed as

ApyraseBiomarkers, TumorCD8-Positive T-LymphocytesLymphocytes, Tumor-InfiltratingNeoplasmsAnimalsAntigens, CDHumansImmune ToleranceAntigens, CDApyraseBiomarkers, TumorCD39 antigenENTPD1 protein, humanadenosineCD39CD8+ TILsimmune checkpoint blockadeT‐cell exhaustiontumour microenvironmenttumour reactivity

Identifiers

PMID42847334
PMCPMC13647484

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.